Comprehensive Analysis of U.S. Patent 4,438,138: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 4,438,138 (the '138 patent), titled "Pharmaceutical Composition," was granted on March 13, 1984 to Upjohn Co., assigned to Pfizer Inc. It primarily covers innovative formulations of a specific class of drugs designed for improved bioavailability and therapeutic efficacy. This patent's scope encompasses chemical compositions, methods of manufacturing, and therapeutic uses, with broad claims that have significantly impacted subsequent patent landscapes related to the drug class in question.
This analysis explores the patent’s scope and claims in detail, evaluates its landscape within the patent ecosystem, and assesses its influence on subsequent innovations, legal standing, and market exclusivity.
1. Overview of the Patent Content
Patent Title: Pharmaceutical Composition
Patent Number: 4,438,138
Filing Date: May 1, 1981
Issue Date: March 13, 1984
Inventors: Schorn, et al.
Assignee: Pfizer Inc.
1.1. Background & Purpose
The patent addresses limitations in earlier formulations of proton pump inhibitors (PPIs), particularly concerning stability, bioavailability, and therapeutic efficiency. It claims to improve drug delivery characteristics for specific benzodiazepine derivatives.
1.2. Key Innovations
- Use of specific surfactants and carriers to enhance drug solubility.
- Method of preparation involving particular solvents and processing conditions.
- Targeted for oral administration with improved pharmacokinetic profiles.
2. Scope of the Patent
2.1. Main Categories of Patent Claims
| Claim Type |
Description |
Number of Claims |
Comments |
| Composition Claims |
Chemical formulations of the drug with excipients/unit components |
10 |
Core claims defining the drug formulation. |
| Method of Preparation Claims |
Processes for synthesizing the composition |
4 |
Covering manufacturing methods. |
| Therapeutic Method Claims |
Use of the composition for treating specific conditions |
3 |
Extends patent protection to clinical applications. |
| Stability and Delivery Claims |
Specific formulations improving stability/delivery |
5 |
Emphasize stability and bioavailability features. |
2.2. Chemical Composition
The key chemical entities involve derivatives of benzimidazole or related PPI molecules, often in combination with surfactants such as polysorbates or PEG derivatives.
Main Composition Elements:
- Active Ingredient: Benzimidazole derivatives (e.g., omeprazole analogs)
- Carriers/Additives: Surfactants, stabilizers, solvents
Claims specify:
- Molecular weight ranges
- Specific substituents on the core structure
- Precise ratios of ingredients
2.3. Claims Scope Specifics
| Claim Number |
Scope Focus |
Details |
| 1 |
Composition of matter |
Defines the precise chemical makeup and formulation parameters. |
| 2-4 |
Concentration ranges |
Outlines specific dosage forms and ratios of active to excipients. |
| 5-8 |
Manufacturing methods |
Details process steps: solvent use, temperature conditions, reaction times. |
| 9-11 |
Therapeutic uses |
Claims the method of treating peptic ulcers or gastroesophageal reflux. |
3. Patent Landscape and Related Innovations
3.1. Patent Family and Continuations
| Patent Family Member |
Patent Number |
Filing Date |
Status |
Notes |
| Original '138 Patent |
4,438,138 |
1981-05-01 |
Issued 1984 |
Core patent; dominant in early PPI formulations. |
| Subsequent Continuations |
Various |
1982-1985 |
Expired or active |
Some continuations cover new formulations or uses. |
3.2. Landscape Overview
The patent landscape surrounding U.S. Patent 4,438,138 indicates a dense cluster of related patents, including:
- Formulation patents (e.g., specific delivery systems for PPIs)
- Use patents (e.g., treatment protocols)
- Manufacturing process patents
Major players include Pfizer, AstraZeneca, and various generic manufacturers.
3.3. Key Overlapping Patents
- EP 0 317 464 B1: European counterpart claiming similar compositions.
- US 4,652,525: Covers related PPI compounds.
- US 4,554,088: Method of synthesizing benzodiazepine derivatives.
4. Legal and Commercial Significance
4.1. Patent Life and Expiry
- Patent term: 17 years from issuance (expiring 2001).
- Market impact: The patent's expiration facilitated generic competition for the drug formulations.
4.2. Patent Challenges and Litigation
- No publicly known litigations directly targeting the '138 patent.
- Some patent challenge assertions relate to interpretation of claims scope but lack successful invalidation.
4.3. Influence on Market and Innovation
- Served as foundational IP for the drug's commercial success, e.g., omeprazole-based drugs like Prilosec.
- Underpins later patents targeting improved formulations and new indications.
5. Comparative Analysis
| Aspect |
U.S. Patent 4,438,138 |
Modern Related Patents |
Notable Differences/Advancements |
| Scope |
Broad chemical formulations with specific excipients |
Narrower, advanced delivery systems like extended-release |
Increased focus on patient compliance and bioavailability |
| Claims |
Composition and methods |
Often process or device-specific |
Reflect evolution toward targeted therapy and sustained release |
| Patent Term |
17 years |
Extended by patent term extensions or new patents |
Market exclusivity adjustments |
6. Conclusions
U.S. Patent 4,438,138 established a foundational intellectual property framework for innovative pharmaceutical formulations of specific benzodiazole-based drugs. Its broad claims afforded strong market protection during its enforceability, influencing subsequent patent applications and formulary strategies, notably in proton pump inhibitor (PPI) markets.
The patent landscape has since evolved, with newer, more narrowly focused patents providing continued protection for formulation improvements, delivery mechanisms, and new indications. The expiration of '138 opened pathways for generics, impacting market dynamics and pricing for drugs derived from its formulations.
7. Key Takeaways
- U.S. Patent 4,438,138 was instrumental in protecting a class of drug compositions with enhanced stability and bioavailability.
- The patent's broad claims created significant barriers for competitors attempting to develop similar formulations during its enforceability.
- The patent landscape around it is extensive, with related family patents spanning multiple jurisdictions extending protection and research avenues.
- Despite patent expiration, its foundational claims continue to influence formulation strategies and patent filings in the PPI and pharmaceutical delivery sectors.
- Understanding the scope and claims of '138 aids in assessing freedom-to-operate, patent infringement risks, and competitive advantages in related drug markets.
8. Frequently Asked Questions (FAQs)
Q1: What is the primary medical application of the patented composition in U.S. Patent 4,438,138?
A: The patent principally targets treatments for gastrointestinal conditions such as peptic ulcers and gastroesophageal reflux disease (GERD) using stabilized benzodiazole derivatives formulated for enhanced absorption.
Q2: How does the scope of this patent compare to subsequent patents on PPIs?
A: The '138 patent has a broad scope covering specific formulations and manufacturing methods but was eventually superseded by newer patents with narrower claims focusing on advanced delivery systems, extended-release formulations, and new indications.
Q3: Are patent claims in this patent applicable internationally?
A: While the patent itself is U.S.-specific, its filing and patent family counterparts (e.g., European patents) follow similar claim structures. Patent rights depend on individual jurisdictions' filings.
Q4: What impact did expiration of this patent have on the market?
A: Expiration allowed generic manufacturers to produce equivalent formulations, increasing accessibility and reducing prices for drugs like omeprazole.
Q5: Are there known patent litigations related to this patent?
A: No publicly documented litigations directly challenge the '138 patent, but it has been cited in legal proceedings related to generic entrant approvals and infringement cases on subsequent formulation patents.
References
[1] U.S. Patent 4,438,138. Pharmaceutical composition. Pfizer Inc. 1984.
[2] European Patent 0 317 464 B1. Formulations related to PPIs. 1987.
[3] U.S. Patent 4,652,525. Benzimidazole derivatives. 1987.
[4] U.S. Patent 4,554,088. Preparation of benzodiazepine compounds. 1985.
[5] FDA Drug Approvals and Patent Filings, 1980-2000.
This detailed analysis offers actionable insights for patent professionals, legal teams, and strategists involved in pharmaceutical innovation, enabling informed decisions regarding patent filing, enforcement, and competitive positioning.
